Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system
FQ-induced hypoglycemia tends to occur early and can have serious consequences. Our preliminary findings provide a better understanding and emphasize the need for enhanced monitoring of potential hypoglycemia linked to FQ treatment.
Authors
- Zi Xue Xuan
- Yuan Zhang (ORCID: https://orcid.org/0000-0001-7377-6334)
- Y. Chen
- Li Chen (ORCID: https://orcid.org/0000-0002-5771-9740)
- Dan Li (ORCID: https://orcid.org/0000-0002-9783-5340)
- Jia Chen (ORCID: https://orcid.org/0000-0002-4242-2899)
- Lei Cheng (ORCID: https://orcid.org/0000-0002-4204-8462)
- Xiaohong Zhou (ORCID: https://orcid.org/0000-0003-4628-8508)
- Feng Guo (ORCID: https://orcid.org/0000-0001-9627-7722)
- Yun Chen (ORCID: https://orcid.org/0009-0004-7275-6525)
- Yuqi Wang (ORCID: https://orcid.org/0000-0001-6230-0330)
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- Chengdu University (CN)
- Hangzhou Medical College (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-05-02
- DOI
- https://doi.org/10.3389/fmed.2025.1583093
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00